Drug
Brensocatib
Brensocatib: highest development phase Phase 3, developed by Insmed. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Insmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brensocatib NCT04817332 | Phase 3 | Covid19 |
| Brensocatib 10 mg NCT04594369 | Phase 3 | Non-Cystic Fibrosis Bronchiectasis |
| Brensocatib 10 mg NCT03218917 | Phase 2 | Non-Cystic Fibrosis Bronchiectasis |
| Brensocatib NCT06013241 | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps |
| Brensocatib NCT05090904 | Phase 2 | Cystic Fibrosis |
| Brensocatib NCT06685835 | Phase 2 | Hidradenitis Suppurativa |
| Brensocatib NCT06178783 | Phase 1 | Healthy Volunteers |
| Brensocatib Oral Solution NCT06344728 | Phase 1 | Healthy Participants |
| Brensocatib NCT05673603 | Phase 1 | Renal Impairment |
| Brensocatib NCT05965570 | Phase 1 | Healthy Volunteers |
| Brensocatib NCT05826574 | Phase 1 | Healthy Volunteers |
| Brensocatib NCT05355935 | Phase 1 | Healthy Volunteer |
| Brensocatib NCT05517525 | Phase 1 | Hepatic Impairment |
| Brensocatib NCT07859007 | Phase 1 |
Latest
No recent events.
Follow Brensocatib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.